Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/309% above fair value
$9.86+0.16 (+1.65%)
Close on Nov 16, 2026Market cap $1.38BP/E –Yield –
Intellia Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Intellia Therapeutics
Intellia Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?